Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Choledochal cyst Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Choledochal cyst indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Biliary atresia Indication Strategy Report 2026: TGF-beta, Trials and Deals
3 August 2026
2026 Biliary atresia indication strategy covering epidemiology, TGF-beta biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Alagille syndrome Indication Strategy Report 2026: NOTCH2, Trials and Deals
3 August 2026
2026 Alagille syndrome indication strategy covering epidemiology, NOTCH2 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Caroli disease Indication Strategy Report 2026: PKD1, Trials and Deals
3 August 2026
2026 Caroli disease indication strategy covering epidemiology, PKD1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Small-duct primary sclerosing cholangitis Indication Strategy Report 2026: FXR, Trials and Deals
3 August 2026
2026 Small-duct primary sclerosing cholangitis indication strategy covering epidemiology, FXR biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Occult hepatitis B infection Indication Strategy Report 2026: HBV polymerase, Trials and Deals
3 August 2026
2026 Occult hepatitis B infection indication strategy covering epidemiology, HBV polymerase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Autoimmune hepatitis type 1 Indication Strategy Report 2026: JAK, Trials and Deals
3 August 2026
2026 Autoimmune hepatitis type 1 indication strategy covering epidemiology, JAK biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Hepatitis E infection Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Hepatitis E infection indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Subacute sclerosing panencephalitis Indication Strategy Report 2026: Measles polymerase, Trials and Deals
3 August 2026
2026 Subacute sclerosing panencephalitis indication strategy covering epidemiology, Measles polymerase biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Fusariosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Fusariosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Congenital rubella syndrome Indication Strategy Report 2026: Viral polymerase, Trials and Deals
3 August 2026
2026 Congenital rubella syndrome indication strategy covering epidemiology, Viral polymerase biology, active trials, transactions, unmet need, competition and…
Latest Hotspot
8 min read
Scedosporiosis Indication Strategy Report 2026: CYP51, Trials and Deals
3 August 2026
2026 Scedosporiosis indication strategy covering epidemiology, CYP51 biology, active trials, transactions, unmet need, competition and market attractiveness.